Samuel Klein on GLP-1 Revolution, Metabolism, and the Future of Obesity Medicine
Vorschaubild von YouTube. Abspielen lädt den YouTube-Player.
Verlauf & EmpfehlungenAus
Zuletzt angesehene Inhalte in diesem Browser behalten. Dein Verlauf bleibt auf diesem Gerät und wird nicht an Harbor gesendet. Abgespielte Videos können auch passende Videoempfehlungen sortieren.
Merkliste & Verlauf öffnen →Über dieses Video
Creator-Beschreibung · OriginaltextTextsprache: Englisch
Dr. Samuel Klein, Division Chief and William H. Danforth Professor of Medicine and Nutritional Science at Washington University Medicine, joins The Future of Medicine for a conversation about obesity, metabolism, insulin resistance, and the revolution sparked by GLP-1 medications like Ozempic.
In this episode, Dr. Klein explains why obesity is far more biologically complex than many people realize — and why some individuals with obesity remain metabolically healthy while others develop diabetes, heart disease, and fatty liver disease.
The conversation explores how fat functions not only as stored energy, but also as an active endocrine organ that communicates with the rest of the body through hormones and inflammatory signaling molecules. Dr. Klein discusses visceral fat, insulin resistance, inflammation, and why procedures like liposuction do not produce the same metabolic benefits as weight loss through diet, surgery, or GLP-1 medications.
Dr. Klein also reflects on the unexpected rise of GLP-1 therapies, including how medications originally developed for diabetes transformed obesity treatment and may hold broader implications for cardiovascular disease, addiction, and other chronic conditions.
Together, Dr. Klein and Euan Ashley discuss the future of metabolic medicine, precision approaches to obesity care, and why understanding metabolism may reshape the future of healthcare itself.
Thank you for watching!
🔔 Subscribe for more conversations on groundbreaking medical science and innovation.
Links:
– Listen to the podcast: https://thefutureofmedicine.buzzsprout.com
– Subscribe to our channel: @stanforddepartmentofmedicine
Chapters
00:00 GLP-1 Therapy Impact
01:55 Obesity & Metabolism
03:43 Obesity: Not Always Bad ️
05:11 Fat Tissue Signals
07:05 Fat: Endocrine Function
09:02 Insulin Resistance
11:29 Liposuction Studies
12:58 Visceral Fat Impact
14:31 GLP-1 Medications
16:55 GLP-1 Unexpected Use
18:30 Metabolically Healthy
20:46 Inflammation Question
22:32 Precision Medicine
25:50 Multi-Organ System
27:22 Future of Medicine
Stanford Department of Medicine · 28 min · Quelle veröffentlicht: 2026-05-25
Zu Harbor hinzugefügt: 23.10.2026
Original auf YouTube ↗Automatisch eingeordnete Quelle. Creator-Aussagen sind keine unabhängige Evidenzprüfung und keine persönliche medizinische Beratung.